Literature DB >> 17461418

A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C.

Hongjin Huang1, Mitchell L Shiffman, Scott Friedman, Ramasubbu Venkatesh, Natalie Bzowej, Olivia T Abar, Charles M Rowland, Joseph J Catanese, Diane U Leong, John J Sninsky, Thomas J Layden, Teresa L Wright, Thomas White, Ramsey C Cheung.   

Abstract

UNLABELLED: Clinical factors such as age, gender, alcohol use, and age-at-infection influence the progression to cirrhosis but cannot accurately predict the risk of developing cirrhosis in patients with chronic hepatitis C (CHC). The aim of this study was to develop a predictive signature for cirrhosis in Caucasian patients. All patients had well-characterized liver histology and clinical factors; DNA was extracted from whole blood for genotyping. We validated all significant markers from a genome scan in the training cohort, and selected 361 markers for the signature building. Using a "machine learning" approach, a signature consisting of markers most predictive for cirrhosis risk in Caucasian patients was developed in the training set (N = 420). The Cirrhosis Risk Score (CRS) was calculated to estimate the risk of developing cirrhosis for each patient. The CRS performance was then tested in an independently enrolled validation cohort of 154 Caucasian patients. A CRS signature consisting of 7 markers was developed for Caucasian patients. The area-under-the-ROC curves (AUC) of the CRS was 0.75 in the training cohort. In the validation cohort, AUC was only 0.53 for clinical factors, increased to 0.73 for CRS, and 0.76 when CRS and clinical factors were combined. A low CRS cutoff of <0.50 to identify low-risk patients would misclassify only 10.3% of high-risk patients, while a high cutoff of >0.70 to identify high-risk patients would misclassify 22.3% of low-risk patients.
CONCLUSION: CRS is a better predictor than clinical factors in differentiating high-risk versus low-risk for cirrhosis in Caucasian CHC patients. Prospective studies should be conducted to further validate these findings.

Entities:  

Mesh:

Year:  2007        PMID: 17461418     DOI: 10.1002/hep.21695

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  112 in total

1.  Toll-like receptor deficiency worsens inflammation and lymphedema after lymphatic injury.

Authors:  Jamie C Zampell; Sonia Elhadad; Tomer Avraham; Evan Weitman; Seth Aschen; Alan Yan; Babak J Mehrara
Journal:  Am J Physiol Cell Physiol       Date:  2011-11-02       Impact factor: 4.249

2.  A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis.

Authors:  Andrew J Paris; Zohar Snapir; Cindy D Christopherson; Shirley Y Kwok; Ursula E Lee; Zahra Ghiassi-Nejad; Peri Kocabayoglu; John J Sninsky; Josep M Llovet; Chaim Kahana; Scott L Friedman
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

Review 3.  Pericytes in the Liver.

Authors:  Enis Kostallari; Vijay H Shah
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

4.  The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases.

Authors:  João-Bruno Soares; Pedro Pimentel-Nunes; Roberto Roncon-Albuquerque; Adelino Leite-Moreira
Journal:  Hepatol Int       Date:  2010-10-21       Impact factor: 6.047

5.  Role of genetic polymorphisms in hepatitis C virus chronic infection.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Caterina Sagnelli; Lorenzo Onorato; Evangelista Sagnelli
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

6.  Association of genetic variants with rapid fibrosis: progression after liver transplantation for hepatitis C.

Authors:  Jennifer E Layden; Bamidele O Tayo; Scott J Cotler; Nina M Clark; Kristine Baraoidan; Scott L Friedman; Richard S Cooper
Journal:  Transplantation       Date:  2014-05-27       Impact factor: 4.939

7.  Microbiome-Immune Interactions and Liver Disease.

Authors:  James H Tabibian; Cyril Varghese; Steven P O'Hara; Nicholas F LaRusso
Journal:  Clin Liver Dis (Hoboken)       Date:  2015-05-07

Review 8.  Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.

Authors:  Valerio Giannelli; Vincenza Di Gregorio; Valerio Iebba; Michela Giusto; Serena Schippa; Manuela Merli; Ulrich Thalheimer
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 9.  Regulation of wound healing and organ fibrosis by toll-like receptors.

Authors:  Peter Huebener; Robert F Schwabe
Journal:  Biochim Biophys Acta       Date:  2012-12-04

Review 10.  Mouse models for liver cancer.

Authors:  Latifa Bakiri; Erwin F Wagner
Journal:  Mol Oncol       Date:  2013-02-05       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.